Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with a 30% mortality rate, making it the most fatal form of skin cancer. Unlike melanoma or basal cell carcinoma, which dominate public awareness, MCC remains largely unknown. The disease is particularly dangerous because it often appears as an asymptomatic bump that can be easily mistaken for other skin conditions, leading to delayed treatment. What makes MCC even more concerning is that patients living in rural areas face significantly worse outcomes than those in urban centers, a disparity driven by healthcare access barriers rather than the disease itself .

What Is Merkel Cell Carcinoma and Why Is It So Dangerous?

Merkel cell carcinoma was first described in 1972 as "trabecular carcinoma of the skin" by pathologist Cyril Toker. The name changed later because the cancer closely resembles Merkel cells, specialized sensory cells in the skin. MCC is invasive and has a high risk of recurrence and metastasis, meaning it can spread to other parts of the body. The disease gained wider public attention in 2023 after singer Jimmy Buffett died from MCC, which sparked a significant increase in online searches for information about the condition .

MCC typically affects White male individuals, aging adults, people with weakened immune systems, and those with a history of other cancers. The disease most often appears on the head and neck, followed by the extremities and buttocks. Clinically, MCC presents as an asymptomatic, firm dome-shaped bump that may be violaceous, pink, or red in color, and it can sometimes show signs of ulceration. Because MCC can resemble other skin conditions like amelanotic melanoma, basal cell carcinoma, squamous cell carcinoma, and even abscesses, misdiagnosis is common, which delays proper treatment .

Why Are Cases Rising and What Causes MCC?

Merkel cell carcinoma cases are increasing worldwide, with the highest rates in Australia and New Zealand. In the United States, cases are expected to rise significantly. Researchers predict approximately 3,200 new MCC cases will be diagnosed in the U.S. in 2025, compared to 2,488 cases in 2013. This increase is suspected to be driven by an aging population and increased ultraviolet (UV) exposure. Additionally, advances in diagnostic staining techniques, particularly cytokeratin 20 (CK20) immunohistochemistry staining that emerged in the 1990s, have improved MCC detection and may account for some of the rise in reported cases .

The underlying causes of MCC involve multiple factors. Merkel cell polyomavirus (MCPyV) has been detected in up to 80% of MCC cases and is believed to play a significant role in cancer development. MCPyV is part of the normal human skin virome and can be found on healthy skin, but it appears to become carcinogenic when it integrates with the host genome and undergoes mutations. UV exposure is suspected to contribute to the transformation of MCPyV from a benign virus to a cancer-causing agent. In cases where MCPyV is not detected, MCC is thought to involve mutations in tumor suppressor genes such as RB1 and TP53, often triggered by UV damage .

How Is MCC Diagnosed and Staged?

Diagnosis of Merkel cell carcinoma requires histopathological and immunohistochemical examination of tissue samples. The National Comprehensive Cancer Network (NCCN) recommends an immunopanel that includes CK20 and thyroid transcription factor 1 (TTF-1) for initial workup. Once a biopsy confirms MCC, patients should undergo comprehensive imaging to determine if the cancer has spread. This typically includes full-body positron emission tomography (PET) or computed tomography (CT) scans of the chest, abdomen, and pelvis with contrast. If the primary lesion is on the head or neck, CT imaging of that area is also recommended. Evaluation of lymph nodes is essential for all patients, and if no lymph node involvement is detected on physical exam or imaging, a sentinel lymph node biopsy is advised to check for early spread .

Why Do Rural Patients Have Worse Outcomes?

Despite presenting with locally staged disease initially, rural patients with MCC have significantly worse outcomes compared to urban patients. The United States Census Bureau defines rural as populations under 50,000 people, and approximately 19% of the total U.S. population lives in rural areas, which encompass 97% of the total land area. Rural patients face multiple barriers that contribute to poorer health outcomes. These patients are less likely to wear sunscreen, less likely to undergo skin cancer screening exams, and experience longer intervals between dermatology appointments due to limited access to dermatology care. These circumstances often result in advanced disease by the time of diagnosis .

The case presented in the medical literature illustrates these challenges. An 80-year-old White male patient residing in a northern rural state with limited dermatology access presented with a rapidly growing lesion on his forearm that had been enlarging for two months. After diagnosis and treatment with wide local excision and immunotherapy with pembrolizumab, the patient developed recurrent MCC two years later in the same location, followed by another new lesion two months after that. This case demonstrates not only the aggressive nature of MCC but also the difficulty of managing the disease in rural settings where follow-up care and specialized treatment options may be limited .

Steps to Improve MCC Detection and Management in Rural Areas

• Increase Public Awareness: Public knowledge of MCC remains limited due to its low incidence and lack of awareness. Educational campaigns targeting rural communities about the signs and symptoms of MCC, including asymptomatic firm bumps on sun-exposed areas, could lead to earlier detection and better outcomes.
• Expand Telemedicine and Specialist Access: Rural patients often encounter challenges involving travel, limited access to care, and financial hardship compared to urban patients. Telemedicine consultations with dermatologists and oncologists could reduce travel burden and improve access to specialized care for diagnosis and treatment planning.
• Strengthen Sun Protection Education: Rural patients, particularly those in farming and outdoor occupations, are less likely to wear sunscreen and have persistent UV exposure. Targeted education about UV protection, including sunscreen use and protective clothing, could reduce MCC risk in high-exposure populations.
• Implement Screening Programs: Currently, no screening tests are in place for MCC or recurrent MCC. Developing and implementing screening protocols in rural areas, particularly for high-risk populations such as elderly White males with occupational sun exposure, could enable earlier diagnosis when disease is more treatable.
• Address Clinical Adherence Barriers: Treating rural patients poses challenges to clinicians involving access to care barriers, patient nonadherence, and financial constraints. Developing support systems, financial assistance programs, and flexible treatment schedules could improve treatment adherence and outcomes.

What Treatment Options Are Available for MCC?

Standard treatment for Merkel cell carcinoma involves wide local surgical excision, which can be complex and requires careful planning to achieve adequate margins while minimizing cosmetic and functional damage. Radiation therapy is often used as an adjuvant treatment to reduce the risk of recurrence. Adjuvant immunotherapy and targeted therapies are emerging as promising treatment options and continue to evolve. Pembrolizumab, an immunotherapy drug, has shown benefit in treating MCC by helping the immune system recognize and attack cancer cells. These newer treatment approaches offer hope for improving outcomes, particularly for patients with advanced or recurrent disease .

The challenge for rural patients is accessing these specialized treatments. Many rural areas lack surgical oncologists, radiation oncologists, and access to newer immunotherapy drugs. This geographic disparity in treatment availability contributes to the worse outcomes observed in rural MCC patients. Addressing these disparities requires coordinated efforts between healthcare systems, policymakers, and the medical community to ensure that all patients, regardless of where they live, have access to evidence-based MCC treatment.

Merkel cell carcinoma represents a significant but underrecognized threat to public health, particularly in rural communities. While the disease is rare, its aggressive nature and high mortality rate demand greater awareness among both patients and healthcare providers. Improving early detection through increased public education, expanding access to specialized care through telemedicine and other innovations, and strengthening sun protection efforts could help reduce the burden of this deadly disease and narrow the gap in outcomes between rural and urban patients.